Embracing the Trend of Precision Medicine: LabTurbo to List on the Strategic New Board on December 22nd
- tssdnews
- 12/22/2023
From Yuanta Securities’ guidance, LabTurbo (7725), a pioneer in the development of nucleic acid extraction and genetic testing technology, will be listed on the Emerging Stock Market (Strategic New Board) with a reference price of NT$32 per share on December 22nd. Simultaneously, in conjunction with the Emerging Stock Market, it will be integrated into the general board of the Emerging Stock Market on January 1st next year, injecting new vitality into the “biotech and medical” sector.
LabTurbo primarily focuses on the research and development of automated nucleic acid application technology. Their flagship products include nucleic acid extraction, genetic testing instruments, reagents, and testing services. Their independently developed “LabTurbo AIO Fully Automated Nucleic Acid Extraction Genetic Testing System” enables an efficient workflow where “samples go in, results come out.” This system effectively reduces human operation errors and the risk of cross-contamination, significantly improving testing efficiency within limited time and space. The product has been adopted by numerous medical centers and regional hospitals in Taiwan and expanded to regions such as the United States and Europe.
Chairman Dai Zihuang stated that LabTurbo’s automated nucleic acid extraction system utilizes “flow-through single-tube vacuum” technology, which can simultaneously detect multiple nucleic acid targets, achieving the function of multiple pathogen detection from a single sample. The company is dedicated to the research and development of multi-pathogen detection reagents. Currently, the product can simultaneously detect multiple genes, with advantages of real-time results, high sensitivity, and specificity. It has been successfully applied in the typing of respiratory viruses and dengue viruses, providing rapid results for precise diagnosis by doctors and making outstanding contributions to global “precision medicine.”
Yuanta Securities’ General Manager, Zhang Yuqi, pointed out that LabTurbo’s technological achievements are outstanding. They have achieved success in nucleic acid testing for Lyme disease, which was applied by the American Red Cross and published in the prestigious medical journal NEJM. Additionally, during the past COVID-19 pandemic, they successfully increased Taiwan’s PCR testing capacity. The company has now expanded its research and development efforts into the field of bloodborne infection testing. In the future, it is expected to assist in the treatment of bacteremia and sepsis patients, helping doctors quickly formulate treatment plans and reduce patient mortality rates. Looking ahead, with the increasing demand for genetic testing and precision medicine, LabTurbo’s performance in both domestic and international markets is highly anticipated.
Yuanta Securities has a professional and dedicated underwriting team, tirelessly discovering high-quality companies to enter the capital market. They also provide customized fundraising and financial advisory services, introducing comprehensive resources to companies and aligning with international trends.